Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-07-31
1997-10-28
Cain, Edward J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3716
Patent
active
056818114
ABSTRACT:
A stabilized conjugated therapeutic agent complex comprising a therapeutic agent conjugatively coupled to a polymer including lipophilic and hydrophilic moieties, wherein the therapeutic agent may for example be selected from the group consisting of insulin, calcitonin, ACTH, glucagon, somatostatin, somatotropin, somatomedin, parathyroid hormone, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, non-naturally occurring opioids, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminease, adenosine deaminase, ribonuclease, trypsin, chymotrypsin, papain, Ara-A (Arabinofuranosyladenine), Acylguanosine, Nordeoxyguanosine, Azidothymidine, Dideoxyadenosine, Dideoxycytidine, Dideoxyinosine Floxuridine, 6-Mercaptopurine, Doxorubicin, Daunorubicin, or I-darubicin, Erythormycin, Vancomycin, oleandomycin, Ampicillin; Quinidine and Heparin. In a particular aspect, the invention comprises an insulin composition suitable for parenteral as well as non-parenteral administration, preferably oral or parenteral administration, comprising insulin covalently coupled with a polymer including (i) a linear polyalkylene glycol moiety and (ii) a lipophilic moiety, wherein the insulin, the linear polyalkylene glycol moiety and the lipophilic moiety are conformationally arranged in relation to one another such that the insulin in the composition has an enhanced in vivo resistance to enzymatic degradation, relative to insulin alone. One, two, or three polymer constituents may be covalently attached to the therapeutic agent molecule, with one polymer constituent being preferred. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications, and the therapeutic agent and polymer may be covalently coupled to one another, or alternatively may be associatively coupled to one another, e.g., by hydrogen bonding or other associative bonding relationship.
REFERENCES:
patent: 3256153 (1966-06-01), Heimlich
patent: 4003792 (1977-01-01), Mills et al.
patent: 4044196 (1977-08-01), Huper et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4410547 (1983-10-01), Ueno et al.
patent: 4585754 (1986-04-01), Meisner et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4684524 (1987-08-01), Eckenhoff et al.
patent: 4698264 (1987-10-01), Steinke
patent: 4717566 (1988-01-01), Eckenhoff et al.
patent: 4744976 (1988-05-01), Snipes et al.
patent: 4772471 (1988-09-01), Vanlerberghe et al.
patent: 4797288 (1989-01-01), Sharma et al.
patent: 4840799 (1989-06-01), Appelgren et al.
patent: 4849405 (1989-07-01), Ecanow
patent: 4935246 (1990-06-01), Ahrens
patent: 4963367 (1990-10-01), Ecanow
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5055300 (1991-10-01), Gupta
patent: 5055304 (1991-10-01), Makino et al.
patent: 5093198 (1992-03-01), Speaker et al.
Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res., 1991, 8 (12): pp. 1453-1459.
Boccu, E. et al., "Pharmocokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase," Pharm. Res. Comm., 1982, 14: PP. 11-120.
Igarashi, R. et al., "Biologically Active Peptides Conjugated with Lecithin for DDS" Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater. 1990, 17: pp. 367-368.
Taniguchi, T. et al., "Synthesis of Acyloyl Lysozyme and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats," Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater., 1992, 19: pp. 104-105.
Russell-Jones, G. J., "Vitamin B12 Drug Delivery," Proceed. Intern. Symp. Control. Rel. Bioactive. Mater., 1992, 19: pp. 102-103.
Baudys, M. et al., "Synthesis and Characteristics of Different Glycosylated Derivatives of Insulin," Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater., 1992, 19: pp. 210-211.
Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcell Deffer, Inc., New York, NY, 1992.
Santiago, N. et al., "Oral Immunization of Rats with Influenze Virus M Protein (M1) Microspheres," Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater., 1992, 19: pp. 116-117.
Banting, R. G., et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," The Canadian Med. Assoc. J. 1992, 12: pp. 141-146.
Brange, J. et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): pp. 715-726.
Nucci, et al., "The Therapeutic Value of Poly(ethylene glycol)--Modified Proteins," Ac. Drug. Del. Rev. 1991, 6: pp. 133-151.
Brange, J. et al., "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): pp. 727-734.
Robbins, D.C. et al., "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients," Diabetes, 1987, 36: pp. 838-841.
Maislos, M. et al., "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin," J. Clin. Invest., 1986, 77: pp. 717-723.
Ratner, R. E. et al., "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates," Diabetes, 1990, 39: pp. 728-733.
Oka, K. et al., "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation," Pharm. Res., 1990, 7 (8): pp. 852-855.
Saffran, M. et al., "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science, 1986, 233: pp. 1081-1084.
Abuschowski, A. and F. F. Davis, "Soluble Polymer-Enzyme Adducts," pp. 368-383, Enzymes as Drugs, J.S. Holcenberg, John Wiley, 1981.
Akiyama, M. et al., "The Synthesis of New Derivatives of 1-.beta.-D-Arabinofuranosylcytosine," Chem. Pharm. Bull., 1978, 26(3): p. 981.
Gish, D. T. et al., "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-.beta.-D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity," J. Med. Chem., 1971, 14(12): pp. 1159-1162.
Baker, D.C. et al., "Prodrugs of 9-.beta.-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(O-Acyl) Derivatives," J. Med. Chem., 1978, 21(12): pp. 1218-1221.
Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," The Journal of Biological Chemistry, 1990, 265(11): pp. 6112-6117.
Hong, C. I. et al., "Nucleoside Conjugates. 7. Synthesis and Antitumor Avtivity of 1-.beta.-D-Arabinofuranosylcytosine Conjugates of Ether Lipids," J. Med. Chem., 1986, 29: pp. 2038-2044.
Aoshima, M. et al., "N.sup.4 -Behenoyl-1-.beta.-D-Arabinofuranofuranosylcytosine as a Potential New Antitumor Agent," Cancer Research, 1977, 37: pp. 2481-2486.
Zalipsky, S. et al., "Attachment of Drugs to Polyethylene Glycols," Eur. Polym. J., 1983, 19(12): pp. 1177-1183.
Cain Edward J.
Hultquist Steven J.
Protein Delivery, Inc.
LandOfFree
Conjugation-stabilized therapeutic agent compositions, delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugation-stabilized therapeutic agent compositions, delivery , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugation-stabilized therapeutic agent compositions, delivery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1026124